 Good day everyone and welcome to this investor-intel interview. My name is Mario Drolai. Today we have the pleasure to have with us Mr. André de la Ronde, president of Diagnose, a publicly traded company dedicated to the detection of a critical health problem. Good day André, and welcome to the show. Thank you. Thank you. André's a great day today for Diagnose as we saw this morning new partnership with New Look coming out. Can you outline to us the basic of the transaction for the company and the shareholders going forward? Sure, yeah. So for us we're very lucky. So we've signed a seven-year agreement with New Look and there is some kind of, what I say, a puzzle in the press release because we talk about iris, but iris belongs 100% to New Look. We signed the agreement with New Look. And it's a seven-year agreement. It's very strategic for us because during the pandemic our initial markets were government and hospitals and clinics and because they all shut down most of them anyway because of COVID. So we had to reinvent ourselves and find a new market and then the new market for us is optometry stores and optometry chains. And so this agreement is very strategic for us. The contract covers three things. One is our existing platform. So they're taking our existing platform and putting what we're going to put a call it an optometry interface to it versus a doctor interface. So all the optometrists at New Look will be using the same platform. The second component is we're going to be developing, co-developing a new application to monitor glaucoma to, you know, most of the patients they have. And so we'll be paid to do that. So it's not free, but we're also going to get paid on the per transaction fee after. And thirdly, they want access to our new application that we've been developing and that we announced a proof of concept for predicting a stroke. And so we are going to a clinical trial environment very, very soon. And you will see this announced very soon within a couple of weeks. And so they want access to that test also. So basically this year, we're going to roll out our solution over the next 12 months to 406 sites. Now those are the sites they have today, but New Look is on a growth trajectory and they will be buying more banners in the US and in Europe. So we will grow our platform with them as they grow. So over the next 12 months, we'll be installing all these sites. And next year, we're looking at anywhere between five and eight million dollars in revenue, just with that customer. So that's about it. The big lines is that I'm not going to go into it. It's pretty amazing, but somebody who knows these kinds of business, you know, like you just can have with 406 locations, let's say three, four scans every day, and the type of money that's involved here, it could ramp up. And I'm pretty sure we're going to have some very 2022 interesting numbers in terms of sales. This year will be good too. We're going to revenue this year. We're going to start revenueing in July, but the big numbers are going to be next year because we need to roll out everything. Yeah, awesome. There's going to be a tremendous growth because I'm coming to my second question. I saw over time that you have developed a very interesting network all over the globe in many, many countries in Southeast, in Mexico. These are all countries that they are going to eventually kick in with their numbers. Can you explain to our viewers your vision without adding all these, that strategy of going worldwide with you? Right. So our existing client base that we have signed up, okay, so they were mostly governments in hospitals. So they shut down because of COVID, but it is very clear that they will reopen from now to probably October, November this year. So some of those countries are having a little more difficulty with the virus, but they will reopen. And we believe that with the existing ones that we have in place, if they all restart in, let's say, September October timeframe, this will be adding probably on a yearly basis around $2 million more. We also have very large prospects in the funnel that we've been working on before COVID, but COVID really slowed down. So we have some very, very large optical chains, actually working with the largest one in the world right now. And we are also working with, I would say, small to medium optometry chains also in Europe. We've signed a partner to cover Germany about the German countries and they already have about seven, eight very large prospects for us. In Canada, we have signed up Laptition who's our exclusive distributor outside of Quebec. And they also have five to six very large prospects right now, including the Ontario government and so forth. Also with New Look, we're going to, they have a business development, a new business development unit to go out and do special projects. So as an example, so the Quebec government will be issuing a request for proposal that was supposed to come out last March, but it didn't happen because of 2020, 2020 because of COVID. But now it's, it looks like it's going to come out in mid-summer. So diagnosis and New Look will now bid on this project with the Quebec government to actually screen a million diabetics over three years. So they have 145 point of care in Quebec. So it's very easy for us to work together and come up with the best winning solution for the Quebec government. So this is another business unit type that we will have also going forward. We also, I talked about the clinical trial, so you'll see this in the next few weeks. And in terms of other optomic group, we're concentrating our efforts right now in private clinics around the world. So you saw that we announced a private clinic in Saudi Arabia. So my grubby has 20 private clinics, but the next clinics, 20 private hospitals, very, very big, very high tech. So they will start also running by July, August timeframe in the 20 sites. So we see our future really, really now changing. And we're looking at profitability before the end of the year on a quarterly basis. And the diagnosis will change because now, I guess, is our time. Finally, after all these years. Andre, I'm coming to my third question. I saw that you fall into the eyes of echelon partners, starting to cover the signals. Can you comment on this? Sure. The analyst at echelon did a analyst report on diagnosed and did a very excellent or job actually called all the competitors in the US and in Europe, including Google. And in, I think the report is extremely precise and very important for anybody who wants to follow us. You can find the report on the echelon website under their analyst coverage. Okay, very good. Thank you very much. And for all our viewers, it was Mr. Andre Laron, president of Diagnose. Andre, once again, thank you very much for being on the show. Symbol ADK on the TSS Venture, $45 million market cap company. Andre, we look forward to seeing much more great news like this. And in 2022, it's a good result. Once again, thank you very much, everyone, for being on the show with us today. Thank you. Bye-bye, everyone.